LAUSR

Recommended treatment regimen for human immune deficiency virus (HIV) infection includes protease inhibitors/ritonavir (PIs/r) combined with two‐nucleoside reverse‐transcriptase inhibitors (2NRTIs), which enable to achieve and maintain viral suppression, restore, and preserve immune function. However, there were inconsistent findings on the levels of interleukin‐6 (IL‐6) levels. Systematic review and meta‐analysis were performed to quantify the pooled effects of PIs/r‐based antiretroviral therapy (ART) on serum/plasma IL‐6 levels in people living with the HIV (PLHIV). PubMed, Web of Science, and Embase were searched from the earliest record to November 4, 2020. Data analysis was conducted on Stata version 16 and Review Manager 5.3. A random‐effect model was used to compute a pooled effect size and weighted mean difference (WMD) was considered the summary effect size. Heterogeneity between studies was estimated by Cochrane's Q test (χ2 test) and I2 statistic and subgroup analysis were performed to explore the source of heterogeneity. Initial search identified 3098 records and 5 studies (7 trials) met inclusion criteria. The pooled mean difference in serum/plasma IL‐6 levels from baseline to follow‐up was 0.534 pg/ml (95% confidence interval: −0.012, 1.08, P = 0.05, I2 = 76.4%). In subgroup analysis, there was a significant association between increased serum/plasma IL‐6 levels and age group ≥ 35 years old, baseline CD4+ counts < 350 cell/mm3, and mean viral load ≥ 4.5 log10 copies/ml. We found that serum/plasma IL‐6 levels increased after combined ART among treatment‐naïve individuals who initiated a successful combination of PIs/r with 2NRTIs. This result also highlights the need to monitor serum/plasma IL‐6 levels during antiviral therapy, which may aid in the effective future treatment of systemic inflammation and related disorders following elevated IL‐6 levels.